Real-world outcomes of maintenance therapy post-autologous stem cell transplantation in newly diagnosed multiple myeloma.

ABSTRACT:

Background

In the Republic of Korea, only lenalidomide, bortezomib, ixazomib, and thalidomide monotherapy are available as maintenance therapy post-autologous stem cell transplantation (ASCT).

Methods

To determine whether maintenance therapy confers a survival benefit in the real world, we compared treatment outcomes according to the use and type of maintenance therapy in patients who underwent ASCT following frontline therapy with the triplet regimen of bortezomib, thalidomide, and dexamethasone for newly diagnosed multiple myeloma in 15 nationwide centers.

Results

A total of 512 patients were analyzed (no-maintenance group, n = 359, and maintenance group, n = 153 patients). Among those receiving maintenance therapy, 104 (68%) received thalidomide, 33 (21%) lenalidom

SUBMITTER: Kang KW 

PROVIDER: S-EPMC11796201 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature